Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer
- 202 Downloads
Bone metastases are responsible for most of the morbidity associated with hormone-refractory prostate cancer (HRPC). 153Sm-ethylenediaminetetramethylene phosphonate (153Sm-EDTMP) has been approved for palliation of painful skeletal metastases. We retrospectively investigated the possible synergistic effect on survival of 153Sm-EDTMP (given to HRPC patients for bone pain palliation) and chemotherapy.
Forty-five HRPC patients were evaluated, with a median age of 71 years. The number of metastatic bone sites was ≤10 in 25 patients and >10 in 20 patients. Median serum PSA was 224 ng/ml. Bone pain was mild in 6 patients, moderate in 16, severe in 22 and intolerable in 1. Fifteen patients were only treated with 153Sm-EDTMP (group A), while 30 patients also received chemotherapy (estramustine phosphate or mitoxantrone plus prednisone) at variable times: between 3 and 5 months after 153Sm-EDTMP (14 patients, group B) or within 1 month after 153Sm-EDTMP (16 patients, group C).
Haematological toxicities observed after either regimen were in general mild, consistent with common observations after either 153Sm-EDTMP or chemotherapy, and without any additive adverse effects in the patients receiving both 153Sm-EDTMP and chemotherapy. Bone pain palliation to some degree was induced by 153Sm-EDTMP in 32/45 patients (71.1%), the proportion of patients with a favourable clinical response being significantly higher in group C than in group A (87.5% vs 53.3%, p = 0.0388). Also in terms of biochemical response (serum PSA levels), patients of group C performed significantly better than patients of group A (p = 0.0235). Overall median survival from the time of administration of 153Sm-EDTMP was 15 months in the total cohort of 45 patients, and was significantly longer in group C than in either group B (30 months vs 11 months, p = 0.023) or group A (30 months vs 10 months, p = 0.008).
The results of this study confirm that 153Sm-EDTMP is effective in terms of pain relief and PSA response, with minimal toxicity. When it was administered in combination with chemotherapy, prolonged survival indicated actual clinical benefit, while there were no additive toxicities. These results provide the rationale for future prospective evaluation of combined therapeutic strategies.
KeywordsHormone-refractory prostate cancer 153Sm-EDTMP Chemotherapy Combination therapy Clinical benefit
- 2.McRea LE, Karafin L. Carcinoma of the prostate: metastases, therapy, and survival—A statistical analysis of 500 cases. Int Coll Surg J 1958;29:723–8.Google Scholar
- 15.Serafini AN. Systemic metabolic radiotherapy with samarium-153-EDTMP for the treatment of painful bone metastasis. Quart J Nucl Med 2001;45:91–9.Google Scholar
- 20.Sinzinger H, Weiss K, Granegger S, Ofluogu S, Kratzik CH, Hajek CH. The Vienna protocol on repeated low dose 153Sm-EDTMP therapy includes pain palliation and lesion regression/stabilization (abstract). Eur J Nucl Med 2001;28:1198.Google Scholar
- 21.Riva P, Franceschi G, Riva N, Casi M, Santimaria M. Anti-tumor effectiveness of multiple courses of 153Sm-EDTMP in bone metastasis from different cancers (abstract). Eur J Nucl Med 2001;28:1054.Google Scholar
- 28.Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidene-diphosphonate. J Clin Oncol 2003;21:2869–75.PubMedCrossRefGoogle Scholar
- 37.Laplanche A, Beuzeboc P, Lumbroso J, Di Palma M, Theodore C, Prapotnich D, et al. A phase II trial of docetaxel and samarium in patients with bone metastases from castration-refractory prostate cancer (CRPC) and a response or stabilization after induction docetaxel-estramustine (abstract). Proc Am Soc Clin Oncol 2006;24:4608.Google Scholar
- 38.Widmark A, Linne T, Modig H, Johansson L. Optimizing the time of co-administration of docetaxel and samarium-153 for advanced androgen independent carcinoma of the prostate (abstract). Proc Am Soc Clin Oncol 2003;22:433.Google Scholar